(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 3.46% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Phibro Animal Health's revenue in 2023 is $976,717,000.On average, 3 Wall Street analysts forecast PAHC's revenue for 2024 to be $39,793,336,730, with the lowest PAHC revenue forecast at $39,125,675,256, and the highest PAHC revenue forecast at $40,526,046,999. On average, 3 Wall Street analysts forecast PAHC's revenue for 2025 to be $42,075,917,559, with the lowest PAHC revenue forecast at $42,000,540,344, and the highest PAHC revenue forecast at $42,156,965,279.
In 2026, PAHC is forecast to generate $43,647,012,010 in revenue, with the lowest revenue forecast at $43,567,543,931 and the highest revenue forecast at $43,726,480,089.